Antares files NDA for overactive bladder drug
This article was originally published in Scrip
Executive Summary
Antares Pharma reported that it filed its new drug application (NDA) with the US FDA for Anturol, the firm's transdermal oxybutynin ATD gel, as a treatment for patients with overactive bladder (OAB), or urge incontinence, which is marked by sudden need to urinate.